Posted in | News | Nanoelectronics

Archer’s First-Generation Biochip gFET Design Validated by Joint Fabrication with a Foundry Partner

Archer Materials Limited (“Archer”, the “Company”), a semiconductor company advancing the quantum computing and medical diagnostics industries, has validated its first-generation Biochip graphene field effect transistor (“gFET”) design through a multi-project wafer (“MPW”) run by its external German foundry partner.

Archer’s Biochip gFET chips diced from the 6-inch multi-project wafer. Image Credit: Archer

The gFET device manufacture is also the first joint fabrication between Archer and an external foundry partner, as the final fabrication processes were performed in-house by the Company in Australia. As announced on 13 July 2023, Archer submitted the first-generation Biochip gFET design to a commercial foundry in Germany for an MPW run.

The MPW-produced gFETs were fabricated on a 6-inch wafer and diced into individual chips (Image 1). An MPW is where Archer’s device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The gFET devices have been measured and function as expected, including the demonstration of liquid gating, and are compatible with the Archer Biochip system platform.

This development follows Archer’s previous announcement on 14 September 2023 on the validation of its advanced Biochip gFET designs for multiplexing through a whole four-inch wafer run by a commercial foundry partner in the Netherlands. The MPW and whole wafer gFET fabrication are consistent with Archer validating its chip designs to ensure scalability for the manufacturing process of the Biochip graphene devices. The outcomes of the runs will be used by Archer in the evaluation of foundries that are best suited to Archer’s technology.

The first-generation gFET devices were designed by the Archer team. Archer is continuing discussions with its commercial foundry partners to secure future semiconductor product manufacturing capability and to support technology development of its Biochip, including further plans for device design validations.

Commenting on the first-generation Biochip gFET device design validation, Dr Mohammad Choucair, CEO of Archer, said,

“Archer’s Biochip gFET device designs, including the first-generation and advanced designs for multiplexing, are now on their way towards foundry readiness, as they each have gone from design and into the development stages independently.

“Acting as a ‘lab-on-a-chip’, Archer’s Biochip would have the potential to detect multiple disease samples at once and provide powerful data analytics, which could contribute towards the disruptive, digital transformation occurring in the global medical diagnostics industry.”

Source: http://www.archerx.com.au

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.